Analysts Offer Predictions for Adagene FY2029 Earnings

Adagene Inc. (NASDAQ:ADAG) – HC Wainwright issued their FY2029 EPS estimates for shares of Adagene in a report issued on Monday, January 27th. HC Wainwright analyst A. He anticipates that the company will post earnings per share of ($0.56) for the year. HC Wainwright currently has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Adagene’s current full-year earnings is ($0.65) per share.

Adagene Stock Performance

Shares of NASDAQ ADAG opened at $1.87 on Tuesday. Adagene has a 1 year low of $1.74 and a 1 year high of $4.29. The firm’s 50 day moving average price is $2.04 and its 200 day moving average price is $2.40.

Institutional Trading of Adagene

A number of hedge funds have recently added to or reduced their stakes in ADAG. Catalina Capital Group LLC grew its holdings in Adagene by 129.2% in the fourth quarter. Catalina Capital Group LLC now owns 29,198 shares of the company’s stock valued at $58,000 after purchasing an additional 16,461 shares during the period. Mill Creek Capital Advisors LLC purchased a new stake in shares of Adagene during the 3rd quarter valued at $202,000. Finally, Exome Asset Management LLC increased its holdings in shares of Adagene by 74.1% during the 3rd quarter. Exome Asset Management LLC now owns 262,625 shares of the company’s stock worth $583,000 after buying an additional 111,749 shares during the last quarter. 9.51% of the stock is owned by institutional investors and hedge funds.

About Adagene

Adagene Inc, a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors.